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Letters to the Editorbiology and its relevance to clinical ther-
apy. This is a laudable step along that path.
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Reply to the Editor:
We greatly appreciate the kind remarks
and insightful comments by Konstantinov,
Li, and Reddington concerning our recent
manuscript, “Receptor Tyrosine Kinase and
Phosphoinositide-3 Kinase Signaling in Ma-
lignant Mesothelioma.”
Although constitutive activation of the
PI3K/Akt pathway has been demonstrated
in a number of solid malignancies,
its importance is certainly not limited to
neoplastic cells. In fact, Akt signaling en-
hances vital cellular processes such as gly-
cogen synthesis and nitric oxide produc-
tion. LY294002 is a lead compound in
the development of PI3K inhibitors and is
not available for human trials. However,
we believe that further drug development
could possibly produce a compound with
acceptable toxicity and therapeutic poten-
tial in oncology. We agree that any new
scular Surgery ● February 2006interventions must be applied with caution
in the context of a controlled trial.
Similarly, inhibitors of the insulin-like
growth factor receptor are still in the de-
velopmental phase. While such compounds
have potential as antineoplastic agents, there
is also the potential for toxic effects such as
the development of endocrinopathies. How-
ever, inhibitors of receptor tyrosine kinases
such as epidermal growth factor receptor
(Iressa, Tarceva) and platelet-derived growth
factor receptor (Gleevec) are currently used
in the treatment of solid and hematologic
malignant tumors with acceptable side ef-
fect profiles.
We again thank Konstantinov, Li, and
Reddington for their interest in our work. It
is clear that an understanding of molecular
mechanisms will be requisite for contem-
porary clinicians, particularly those treat-
ing cardiovascular and oncologic disease.
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